Retirement Systems of Alabama Sells 1,207 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Retirement Systems of Alabama lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 1.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 84,342 shares of the medical equipment provider’s stock after selling 1,207 shares during the quarter. Retirement Systems of Alabama’s holdings in Lantheus were worth $9,257,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC bought a new position in Lantheus in the 2nd quarter worth about $290,000. Blue Trust Inc. increased its position in shares of Lantheus by 3,875.9% in the second quarter. Blue Trust Inc. now owns 3,141 shares of the medical equipment provider’s stock worth $252,000 after purchasing an additional 3,062 shares during the last quarter. Raymond James & Associates raised its stake in Lantheus by 43.3% in the second quarter. Raymond James & Associates now owns 25,867 shares of the medical equipment provider’s stock valued at $2,077,000 after purchasing an additional 7,817 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in Lantheus by 4.5% during the second quarter. Nisa Investment Advisors LLC now owns 6,643 shares of the medical equipment provider’s stock valued at $533,000 after purchasing an additional 287 shares during the last quarter. Finally, Shelton Wealth Management LLC bought a new stake in Lantheus during the second quarter valued at approximately $580,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 0.5 %

LNTH opened at $93.48 on Tuesday. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $126.89. The business’s 50-day moving average price is $97.62 and its 200-day moving average price is $98.20. The company has a market cap of $6.50 billion, a P/E ratio of 15.55 and a beta of 0.45.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LNTH. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities lowered their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, Redburn Atlantic initiated coverage on Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $130.00.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.